ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the ...

TUCSON, Ariz. (KGUN) — Diabetics have many options nowadays for their treatment plans. Afrezza is FDA-approved for adults with type 1 or type 2 diabetes as a fast-acting, mealtime insulin, but it ...

Please provide your email address to receive an email when new articles are posted on . Of adults with type 1 diabetes who used technosphere insulin, 38% learned about it from a health care ...

Inhaled insulin could be a better option than injections or pumps for some patients with type 1 diabetes, a new clinical trial shows. About 21% of those on inhaled insulin had a hemoglobin A1C ...

The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

CINCINNATI (WKRC) -A new way to deliver insulin could help people living with diabetes avoid painful injections. Insulin can now be inhaled. James Jones now uses this inhaled insulin instead of the ...

Researchers found that more participants using the inhaled insulin regimen experienced significant improvements in HbA1c levels vs usual care, HealthDay News — Inhaled insulin is associated with ...

MannKind Corp., a biopharmaceutical company based in Danbury, on Saturday announced positive results from a study that showed inhaling insulin is as effective as injecting it for treating adults with ...

Researchers have found in a new study that inhaled insulin showed no increased risk of lung cancer compared with regular human insulin (RAA). However, it was associated with a threefold higher ...

A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...